Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Histone H3
100%
Pancreatic Cancer Cells
100%
Cancer Cell Death
100%
Survivin
100%
Sangivamycin
100%
Haspin
100%
Treatment Options
20%
Tumor
20%
Tumor Cells
20%
Pancreatic Cancer
20%
FDA-approved Drugs
20%
Gemcitabine
20%
Cell Proliferation
20%
Tumor Microenvironment
20%
Current Treatment
20%
5-year Survival
20%
Apoptotic Cell Death
20%
Mitosis
20%
Related Compounds
20%
Implanted Tumor
20%
Nucleoside Analogues
20%
Histone H3 Phosphorylation
20%
Toyocamycin
20%
Mechanistic Insights
20%
New Options
20%
Medicine and Dentistry
Cancer Cell
100%
Pancreas Cancer
100%
Cell Death
100%
Survivin
100%
Histone H3
100%
Sangivamycin
100%
Cell Line
40%
Tumor
40%
Gemcitabine
20%
Phosphotransferase
20%
Programmed Cell Death
20%
Cell Proliferation
20%
Tumor Microenvironment
20%
Tumor Cell
20%
Target Cell
20%
Five-Year Survival Rate
20%
Immunosuppressive Drug
20%
Toyocamycin
20%
Nucleoside Analog
20%
Treatment Option
20%
Mitosis
20%
phosphorylation
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Survivin
100%
Histone H3
100%
Sangivamycin
100%
Neoplasm
20%
Phosphotransferase
20%
Gemcitabine
20%
Tumor Microenvironment
20%
Survival Rate
20%
Immunosuppressive Agent
20%
Toyocamycin
20%
Nucleoside Analog
20%
Chemistry
Histone
100%
Cell Death
100%
Sangivamycin
100%
Apoptotic
20%
phosphorylation
20%
Nucleoside Analog
20%
Gemcitabine
20%
Toyocamycin
20%